KiraGen participated in the Business Track of the 2024 Harvard Business School New Venture Competition, which included 78 teams.
The team presented its solid-tumor cell-therapy strategy and received feedback on the scientific, commercial, and company-building assumptions behind the program.
The feedback informed KiraGen's early development strategy.
